Wolfe Research removed an Outperform rating and moved Autoliv to Peer Perform, reducing a key analyst endorsement. Investors pay about $14 for each $1 Autoliv earned last year, but the rating cut still makes more selling likely.
The Wolfe Research cut removes an above-peer endorsement for Autoliv, which weakens one source of investor confidence. That change makes selling pressure more likely, even though Autoliv's valuation and recent fundamentals still look reasonable.
Raymond James downgraded Accelerant to Underperform, which lowers sell-side support for the stock. Accelerant closed at $19.79 on Tuesday, near its recent high, but the downgrade still reduces positive analyst coverage.
Wedbush cut Compass Therapeutics from Outperform to Neutral and cut the price target from $5 to $1, a large reduction in expectations. That steep cut signals much weaker analyst views and hurts sentiment.
JP Morgan moved Wave Life from Overweight to Neutral, removing a favorable rating. The shares trade near their 52-week low ($4.20), which may limit further downside but does not erase the negative rating change.
UBS cut PG&E from Buy to Neutral and cut its price target from $19 to $14, lowering analyst expectations. PG&E closed at $12.88 on Tuesday, below the new target, yet the downgrade still reduces positive coverage.
Follow Autoliv Inc (ALV) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for ALV